OSAKA, JAPAN & CAMBRIDGE, MASS.--(Business Wire / Korea Newswire)--Takeda (TSE:4502/NYSE:TAK) today announced positive topline results from a randomized, double-blind, placebo-controlled, multiple dose Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist,...